Mantle Cell Lymphoma
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Cecilia BrownMantle Cell Lymphoma | March 13, 2023
A phase I/II trial of LV20.19 showed a 100% ORR in patients with relapsed or refractory MCL.
Read More
Cecilia BrownMantle Cell Lymphoma | March 13, 2023
Benefits of rituximab maintenance were observed despite the shift in first-line induction strategies over the years.
Cecilia BrownMantle Cell Lymphoma | March 7, 2023
Brexucabtagene autoleucel in the standard-of-care setting for R/R MCL showed efficacy and toxicity “consistent” with ...
Kerri FitzgeraldMantle Cell Lymphoma | January 27, 2023
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Tycel Phillips, MDVideo Insights | January 25, 2023
Tycel Phillips, MD, discusses a study evaluating glofitamab in patients with relapsed/refractory mantle cell lymphoma.
Leah SherwoodMantle Cell Lymphoma | January 24, 2023
A phase I/II study of zilovertamab and ibrutinib in R/R MCL showed the combination was well-tolerated.
Advertisement
Cecilia BrownMantle Cell Lymphoma | January 13, 2023
Jonathon Cohen, MD, discusses how he came to focus on lymphoma, as well as current research, pressing questions, and more.
Leah SherwoodPrint | January 13, 2023
Orelabrutinib has been approved by the Health Sciences Authority of Singapore for the treatment of adults with MCL.
Leah LawrencePrint | December 22, 2022
Experts discuss areas of progress and where more work is needed to establish a standard of care in mantle cell lymphoma.
Leah SherwoodMantle Cell Lymphoma | December 19, 2022
The combination of acalabrutinib plus venetoclax and rituximab is well tolerated in treatment-naive MCL.
Leah SherwoodMantle Cell Lymphoma | December 19, 2022
The triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated in MCL.
Cecilia BrownVideo Insights | December 19, 2022
Jean Koff, MD, MSc, discusses research presented at ASH on the genomic characterization of mantle cell lymphoma.
Leah SherwoodMantle Cell Lymphoma | December 19, 2022
David Bond, MD, discusses data on survival following MCL relapse from the LION Prospective Observational Registry.
Leah SherwoodMantle Cell Lymphoma | December 16, 2022
Updated results from the phase I/II BRUIN study showed that pirtobrutinib continues to be well tolerated in R/R MCL.
Chadi Nabhan, MD, MBA, FACPMantle Cell Lymphoma | December 16, 2022
Tycel Phillips, MD, of the City of Hope, talks about the TRIANGLE study and frontline therapy in mantle cell lymphoma.
Leah SherwoodMeeting News | December 14, 2022
Advances in treatment have led to improved outcomes in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Kerri FitzgeraldHodgkin Lymphoma | December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Cecilia BrownMantle Cell Lymphoma | December 10, 2022
High-dose immunochemotherapy and AHSCT “failed to show superiority over” an ibrutinib-containing treatment without AHSCT. ...
Leah SherwoodMantle Cell Lymphoma | November 2, 2022
Regulatory applications were filed for epcoritamab to treat R/R LBCL, DLBCL.
Leah SherwoodMantle Cell Lymphoma | October 17, 2022
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
Advertisement
Advertisement
Editorial Board